Accelerated titration designs - Biometric Research Branch

~~.."" . -" .-~---~-~~.~_...
0
.-
.t
Table 4.3 ( Continued)
Intra patient
dose- Recommended
Author/
reference Agent Schedule Design escalation dose
Borchmann H22xKi-4, bispecific IV days 1,3,5, 4B Yes 80 mg/m2 per cycle
et al. (29) anti-CD30 and CD64 7-21 days
monoclonal antibody
0 ZC/
C/ ..
Gadgeel KRN5500, spicamycin 1 hour iV daily x 5 2B Yes 4.3 mg/m2/day x 5 every
et al. (30) derivative every 3 weeks
3 weeks
Schoemaker MAG-CPT, polymer IV infusion over 3 days Modified 2A No 68 mg/m2/day for 3 days
et at. (31) conjugate of every 4 weeks
every 4 weeks
camptothecin
Matsumura MCC-465, doxorubicin 1 hour IV infusion every ATD No 32.5 mg/m2 every 3 weeks ~
et al. (32) PEG immunoliposome 3 weeks planned n
Clive Antagonist G substance P IV every 3 weeks until Modified 4A No 400 mg/m2 weekly 6 hour
~
et al. (33) analog the target maximum
IV infusion
plasma concentration
~
of 10 p,M then weekly
~
Matsumura NK9l1, micelle IV every 3 weeks Modified 3A No 50 mg/m2 every 3 weeks i- -i et at. (34) encaps!llated doxorubicin
de Jonge PNU -159548, alky1cycline IV every 3 weeks Modified 4B Yes 12 and 14 mg/m2 IV every ~
3 weeks in HP and MP -
et al. (35)
(2 studies)
0
patients
Z
ci
Lockhar PNU -166196A, brostallcin, IV weekly x 3 every Modified 3B Yes 2.4 mg/m2/week tI
et al. (36) a nonalkylating DNA 4 weeks
minor groove binder
';;.::,:,¡:
\~;i::;\,~,.:" .
~~#~,~ii~1¡¥.~'i'Niiml~.~~.,\'..i!~,.~~J!~~~,~'",~~~~,""".~'7'~~,"=-.,-,.~,.~...-,..,,.,./~.".,.....",.._...,,_.,,-.